Zacks Investment Research
05 Oct 2026, 16:55 UTC · 1h ago
Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
Impact · against what's priced in
The article provides a general comparative overview of J&J and Pfizer's oncology exposure and diversification, but contains no new catalysts. For J&J, the mention of its diversified model and dividend history reinforces the current valuation without pushing it toward the higher growth targets the market currently rejects.
- JNJ+0.00
Already priced in
- The price assumes
The raised 2026 revenue guidance of $100.3–$101.3 billion
The article highlights J&J's diversified business model and strong cash flows, which are the foundational drivers of the 2026 revenue guidance the market already assumes.
What JNJ's price assumes · Sep 3
Search tags
